Finalist Judges

Caroline Chu

Vice President, Goldman Sachs Investment Partners

Caroline is an investment professional within Goldman Sachs Investment Management. She joined Goldman Sachs in 2002, and spent two years in Goldman Sachs Investment Research prior to joining an investing group within the Securities Division in 2004. She earned a dual degree in Economics and Management Science from the Massachusetts Institute of Technology in 2002.

Klaus Wilgenbus MD

Corporate Senior Vice President, Boehringer Ingelheim

Klaus Wilgenbus heads Business Development & Licensing/Strategy for Boehringer Ingelheim's (BI) world-wide ethical pharmaceutical business in Ingelheim, Germany. His team is responsible for Strategy/Portfolio Management and BI's global partnering activities ranging from early discovery alliances to co-commercialization arrangements on marketed products.Previously, Klaus Wilgenbus held several management positions within BI, including Vice President R&D Licensing and Director for Exploratory Research in Oncology at BI's R&D Centre in Vienna, Austria. He began his career at BI in 1996 as a senior scientist in Genome Sciences. Klaus Wilgenbus has received his formal training as a physician in Germany and the US. He spent several years in academic research at Stanford University, California and the German Cancer Research Centre Heidelberg, Germany. He is author/co-author of over 20 original scientific publications in peer reviewed scientific journals in the area of Human and Molecular Genetics. Klaus Wilgenbus is an independent Board Member of Karolinksa Development AB.

Tony Sun

Partner Aisling Capital

Dr. Sun joined Fund I in 2002 and currently serves as a Partner. Previously, Dr. Sun was an Adjunct Instructor of Medicine at the Hospital of the University of Pennsylvania. Dr. Sun currently serves as a director of several healthcare and life science companies. He received his M.D. from Temple University School of Medicine with A.O.A. honors. He received his M.B.A. from The Wharton School at the University of Pennsylvania, and his B.S. in Electrical Engineering from Cornell University. In addition, he is Board Certified in Internal Medicine.

Paul Sekhri

Head, Biotech Ops Group, TPG Biotech

Prior to joining TPG Biotech in January 2009 as Head, Biotech Ops Group, Mr. Sekhri was Founder, President, and Chief Executive Officer of Cerimon Pharmaceuticals, Inc.Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc. Prior to ARIAD, Mr. Sekhri joined the Sprout Group (now New Leaf Ventures), where he was a Partner for healthcare technology investments. Mr. Sekhri spent four years at Novartis, most recently as Senior Vice President, and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG. Prior to this, Mr. Sekhri developed the Disease Area Strategy for Novartis, identifying those specific therapeutic areas upon which the company would focus. His first role at Novartis was as Global Head, Early Commercial Development - a department he established to ensure the differential competitive advantage of Novartis' pipeline. Mr. Sekhri completed graduate work in neuroscience at the University of Maryland School of Medicine where he also received his BS in Zoology. Mr. Sekhri is currently a member of the Board of Directors of Affectis Pharmaceuticals, APT Pharmaceuticals, ARYx Therapeutics, KAI Pharmaceuticals, IMS Health, Intercept Pharmaceuticals, Macrogenics, and Moksha8. Additionally he is on the Board of Directors of the Cancer Research Institute (CRI), Ontario Institute for Cancer Research (OICR) Board subcommittee on Commercialization, and the BioExec Institute, Inc. Mr. Sekhri is also an Advisor to the Brookings Global Health Financing Initiative, is an LES M&A Committee member, and was recently elected to the Board of Trustees of Carnegie Hall.

Sabine Luik

Senior Vice President of Medicine and Regulatory Affairs

Dr. Luik serves as the Senior Vice President of Medicine and Regulatory Affairs and is the U.S. Regional Medical Director of Boehringer Ingelheim GmbH. Previously, she held the management position as the Corporate Senior Vice President of Quality, Regulatory, Pharmacovigilance, and Epidemiology.

Rick Lee

President & CEO, Healthrageous

Rick Lee has made a career in the creation and sales of specialty health care applications sold to employers and health plans.He is the CEO of Healthrageous, a behavioral change company launched in 2010 by Partners HealthCare and the Center for Connected Health.

Healthrageous has grown since Series Afunding in May, 2010 to serve 16 employers and 4 BCBS plans. It also has a multi-million dollar engagement with BoehringerIngelheim. The company has 37 employees and is located in Boston's financial district.

Mr. Lee was the President of Employer Solutions, a $125 million Employee Assistance division of Magellan Health Services (NYSE:MGLN) from 2006-2008. He founded Quality Oncology, a cancer disease management firm, in 1995 and was instrumental in the company's growth and ultimate sale to Matria Healthcare in 2003. He was part of the founding team of Value Health, Inc. a specialty managed care company that grew to a $1.5 billion IPO in 3 1/2 years.

Rick is a graduate of Harvard College and the University of Washington School of Public Health, where he received an M.H.A.

Semifinalist Judges

David Boardman

Principal Designer at IDEO

David Boardman is a Principal Designer at IDEO's New York where he leads the Interaction Design discipline. David has several years of experience in designing multichannel ecosystems for financial, entertainment, wellness and healthcare organizations. Prior to join IDEO, David has spent the previous five years working at frog, a global design innovation firm, and researching at MIT Design Lab. He has been a lecturer and taught workshops at MIT, SUPSI – MAIND Lugano, Domus Academy, Universita di Torino, and Universidad de Chile. He presented and exhibited design and media arts projects at international venues such as Ars Electronica, MIT Humanities + Digital Conference, Social Computing Conference, International Journalism Festival, Milan Design Week

Wolfgang Renz

MD, VP, Boehringer Ingelheim

Wolfgang Renz, MD, has over 11 years experience in the pharmaceutical industry. His experience includes multinational CRO, and public pharmaceutical companies. Dr. Renz obtained his medical degree from the University of Freiburg, and is board certified in Emergency Medicine. He completed his PhD in Anatomy at the University of Freiburg, Germany.

Katharine Wolf

Bridges Ventures

Katharine is consulting to Bridges Ventures in the U.S. where she is focused on identifying high-growth, high-impact companies in the health & wellness sector. Previously, Katharine helped to found and runOrganJet, a health care logistics company that helps organ transplant patients travel across the U.S. to receive treatment with the use of private jets. She has also held positions with Asia Impact Investment Exchange (Singapore’s social stock market) and Root Capital (social investment firm). Katharine founded and helped run a microfinance bank in Northern Vietnam. Katharine began her career as an investment banker at Deutsche Bank, where she was an Associate in the Mergers & Acquisitions team in Paris and an analyst in the Leveraged Finance group in New York. Katharine received a BA in Economics and French, with a minor in Mathematics, from Middlebury College, an MBA with a certificate in Public Management from Stanford University's Graduate School of Business, and a Masters-in-Public-Administration in International Development from Harvard Kennedy School of Government.

Dr. Ronald Tamler

MD, Clinical Director, Mount Sinai Diabetes Center

Dr. Tamler, clinical director of the Mount Sinai Diabetes Center, is a board-certified endocrinologist and internist. He is also a nutrition-support physician and certified diabetes educator (CDE). He specializes in Type 1 and Type 2 diabetes and diabetic complications, but also treats patients with general endocrine problems (e.g. low testosterone or thyroid disease). Dr. Tamler's PhD research focused on free radical biology, and he is transferring his experience from the bench to the clinical arena by investigating diabetes-related endothelial dysfunction. He is working closely with the departments of Urology and Cardiology, studying the effects of testosterone on endothelial function. Dr. Tamler has published extensively on the use of nutritional supplements for hormonal issues in general and in Men’s Health specifically. Finally, Dr. Tamler is a sought-after expert on mobile health and the use of smart phone applications for diabetes self-management. He is a frequent speaker at regional, national and international venues on the topic of men's health and diabetes.

In collaboration with Boehringer Ingelheim International, based in Ingelheim, Germany
© 2013 HITLAB